DGX: Rega marang dodolan Quest

Quest Diagnostics is offsetting a slowdown in organic growth through the aggressive acquisition of hospital laboratories. The P/S market multiple clearly demonstrates the dynamics of this expansion, with the 2.40 figure serving as the target level. Business stability relies on an impeccable level of trust from medical professionals, while technological superiority in genetics and automation enables the diagnosis of pathologies at the earliest stages.

The P/S ratio determines the market value of a business relative to its annual sales volume, allowing for an assessment of the premium paid per unit of revenue. By analyzing the P/S time series, an investor can determine the fair value of Quest Diagnostics (DGX), where stable demand for clinical testing minimizes valuation volatility risks due to the predictability of cash flows across any economic cycle.